- Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin…
On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin…
Director Share PurchaseLONDON, UK / ACCESSWIRE / February 22, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical…
LUND, SWEDEN / ACCESSWIRE / February 22, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the…
- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45%…
CALGARY, AB / ACCESSWIRE / February 21, 2024 / ASIA GREEN BIOTECHNOLOGY CORP. (CSE:ASIA) ("Asia Green" or the "Company") is…
Company strengthens its team with highly experienced medical device executives to gear up for a market launch in 2025WASHINGTON--(BUSINESS WIRE)--Otolith…
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech…
Unlocking Prosperity: Business Opportunities Await! All Entrepreneurs Invited to Seize the MomentNAPLES, FL / ACCESSWIRE / February 21, 2024 /…